Background: Initiation or augmentation of pediatric liver transplant programs in the United States faces challenges of limited expertise, small volumes, and regional variation in access to care. PACH launched a prospective plan of pediatric liver program development at two sites (VAUV and FLFH) with the goals of comprehensive multidisciplinary program support, consistent surgical leadership from one team, consensus protocol development, and standardization of perioperative and postoperative care, and comprehensive long‐term follow‐up care plans. A third center, NCCM, was launched in June 2024. Methods: Between January 2016 and December 31, 2024, 140 children received pediatric liver transplants at one of the collaborative sites. A total of 215 PLT were performed at PACH during the same period. Results: Patient and graft survival were 94.4% and 93.2% respectively, with current follow‐up of 1674 ± 1037 days. Overall patient demographics, complications, and patient outcomes were similar among all institutions. Conclusions: A paradigm of systematically extending center experience directly to facilitate safe and high‐quality pediatric liver program establishment has been demonstrated, with the additional benefit of increased split liver graft utilization benefiting both adults and children. The success of this model has implications for optimizing pediatric liver transplant care in the United States.
Background: The Starzl Network for Excellence in Pediatric Transplantation, a learning health network focused on pediatric liver transplantation, identified optimizing immunosuppression as a priority challenge. There remains significant variability in immunosuppression practices across transplant centers and a need for comparative effectiveness research to clarify best practices. As a prelude, we aimed to develop a composite outcome that focuses on immunosuppression‐related morbidity and to characterize its baseline prevalence at 1 year post‐liver transplant. Methods: We developed a composite transplant primary outcome, based on a previously described “ideal outcome” definition utilized by the Society of Pediatric Liver Transplantation registry studies, with components reflecting liver and child health. We used retrospective data from Starzl Network centers to calculate the prevalence of achieving the composite outcome among children who underwent a liver transplant in 2023. Results: In 2023, 19 participating centers transplanted a total of 267 children. Of the 250 with complete data available, 46% were < 2 years of age at transplant, 25% were 2–8 years, 22% were > 8 years, and 7% were missing age data. Seventy‐eight children (31%) achieved the composite outcome at 1 year, including 35% of < 2‐year‐olds, 32% of 2–8 year‐olds, 29% of > 8 year‐olds, and 11% without age available. The most common failed composite outcome criterion was having ALT > 50 IU/L at 1 year. Conclusions: Only 31% of pediatric liver transplant recipients achieved the composite outcome by 1 year. Our network will aim to develop evidence‐based best practices to increase achievement of the composite outcome by “right‐sizing” immunosuppression for each child.
A 12‐year‐old boy presented to our center with elevated aminotransferases, jaundice, right upper quadrant tenderness, and hepatomegaly. Evaluation revealed a highly elevated blood hepatitis C virus (HCV) ribonucleic acid (RNA) level, and liver biopsy showed canalicular and intrahepatic cholestasis, feathery degeneration of hepatocytes, and periportal/perisinusoidal fibrosis. Though there were atypical biopsy features, including absence of bile ductular reaction, we diagnosed suspected fibrosing cholestatic hepatitis (FCH). FCH secondary to HCV infection has been reported exclusively in immunosuppressed adults. To our knowledge, this is the first reported case of suspected FCH in a child, and the first reported case of suspected HCV‐related FCH in any immunocompetent patient. Our patient was successfully treated with sofosbuvir/velpatasvir with sustained virologic response at 12 weeks. We conclude that FCH should be considered on the differential whenever any child with HCV infection presents with evidence of worsening liver injury including new hepatomegaly or jaundice.